"Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies."

During the past decade, Arlington Cancer Center conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 4 clinical trials were completed, i.e. on average, 80% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 3 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Arlington Cancer Center" #1 sponsor was "Telik" with 4 trials, followed by "Bristol-Myers Squibb" with 2 trials sponsored, "Celgene" with 2 trials sponsored, "Gemin X" with 2 trials sponsored and "Novartis Pharmaceuticals" with 2 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Arlington Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 5 trials as a collaborator, "Radiation Therapy Oncology Group" with 3 trials as a collaborator, "Advanced Clinical Research Services, LLC" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Danish Head and Neck Cancer Group" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Arlington Cancer Center" are "Lung Cancer" (3 trials), "Ovarian Neoplasms" (3 trials), "Pancreatic Cancer" (3 trials), "Breast Cancer" (2 trials) and "Lymphoma, Non-Hodgkin" (2 trials). Many other conditions were trialed in "Arlington Cancer Center" in a lesser frequency.

Most popular intervention types in "Arlington Cancer Center" are "Drug" (29 trials), "Biological" (9 trials), "Radiation" (4 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "gemcitabine hydrochloride" (3 trials), "radiation therapy" (3 trials), "Lenalidomide" (2 trials) and "Rituximab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Arlington Cancer Center" are 24 trials for "All" genders, 7 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Arlington Cancer Center". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Arlington Cancer Center, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Arlington Cancer Center, 2 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".